organizations challenging some of Myriad Genetics' patents cov ering the BRCA1 and BRCA2 genes and their use in screening for elevated risks of breast and ovarian cancer. On March 29, in a startling decision, a federal dis trict court judge invalidated many of Myriad's patent claims, 1 re igniting a longsimmering debate about the patentability of genes.
The Patent Act permits exclu sive control for a limited time (currently 20 years) of any "pro cess, machine, manufacture, or composition of matter," and since its inception, the U.S. Patent and Trademark Office (USPTO) has granted patents on new pharma ceuticals and medical devices. However, as recently as the 1970s, the view among many medical researchers and legal scholars, as well as members of the USPTO, was that DNA sequences were not patentable, primarily because DNA is a naturally occurring substance rather than a human invention. This perception changed in 1980 with the Supreme Court's land mark ruling in Diamond v. Chakra barty, 2 which involved a dispute over the patentability of a microbe that dissolves oil and that had been specially constructed to in clude a DNA plasmid. The Court held that although the Patent Act did not authorize ownership of laws of nature, "products of nature," or physical phenomena, "anything under the sun made by man" was patentable, includ ing the humanmade bacterium at issue in the case.
After the decision, gene pat ents -specifically, patents on "isolated DNA" -soon became commonplace. USPTO examiners justified this extension of patent protection on the grounds that the patented genes and DNA se quences had been purified (and therefore transformed) from their natural form through the appli cation of artificial tools. By the 1990s, technological advances in DNAsequencing strategies began enabling scientists to discover and isolate new genes at a rapid rate. Ultimately, thousands of patents were awarded on differ ent parts of the human genome sequence; reportedly, about 20% of human gene DNA sequences are currently patented.
Myriad was founded in 1991 by Walter Gilbert, who won a Nobel Prize for his work in nu cleic acid sequencing, and Mark Skolnick, a geneticist who had spent his career working on the familial characteristics of cancer. A re human genes and the process of comparing DNA sequences patentable? These questions were raised by a group of researchers, pathologists, patients with cancer, and medical professional In 1994, building on publicly funded research on the heredi tary predisposition to breast can cer that had been conducted in several countries throughout the 1980s and using about $22 mil lion in private venture capital, Myriad's team won a race with several other groups to identify the nucleotide sequences compos ing the BRCA1 gene (see time line). Myriad's team included col laborators from the University of Utah, the National Institute of Environmental Health Scienc es, McGill University, and Eli Lilly and was also supported by grants from the National Institutes of Health and the National Cancer Institute of Canada. A year later, Myriad filed for a patent on the BRCA2 gene, although it may not have been the first to identify its sequence. Myriad's patents, the earliest of which expire in 2014 and 2015, cover isolated gene sequences, as well as methods of "analyzing" and "comparing" the gene sequences to determine whether the mutations confer ring an increased risk of breast or ovarian cancer are present. Myriad launched its combined genetic test, BRACAnalysis, in November 1996. In 2009, the test accounted for most of the company's $326 million in an nual revenue from molecular di agnostics. 3 Though the BRCA tests are of undeniable public health impor tance, questions arose about the appropriateness of the underly ing patents. In 2004, the Euro pean Patent Office rejected some of Myriad's patent claims and limited others because they did not meet its legal standard of inventiveness. In the United States, legal scholars argued that the Patent Act does not ap ply to naturally occurring gene sequences, even in their "isolat ed" form, contending that Con gress's constitutional power to grant patents was intended for inventions in the limited sense of human, physical creations. 4 Similarly, Supreme Court prece dent suggested that natural prod ucts and naturally occurring prop erties of living things are legally distinguishable from goods man ufactured using substantial in genuity. From this perspective, DNA sequences are discovered, 
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not invented, and are therefore quite different from genetically engineered products such as those in the Chakrabarty case. Physician groups have voiced concern about the impact that Myriad's patents have on the use of the genetic test in patient care. The BRACAnalysis test, which was initially priced at approxi mately $1,600, had nearly dou bled in cost, to $3,150, by 2009, which may be prohibitively ex pensive for some patients.
Though Myriad reports that insurance covers more than 90% of the cost of 90% of the tests it performs, the number of tests that are forgone because of cost or lack of coverage is unknown. The DNA patents prohibit other entrepreneurs from selling less expensive tests based on the same genes, even if the test technolo gies are different. Physicians also noted that the patents prevented other genetic tests with greater sensitivity or specificity from be ing commercialized. Physician researchers objected that although Myriad allowed free use of its test in research, it barred inves tigators from telling women the results, compromising their eth ical obligations to their patient subjects. Myriad and its support ers responded that gene patents are crucial to attracting private capital investment and stimulat ing research and development in fields such as personalized med icine.
In invalidating Myriad's pat ents on the DNA sequences, U.S. District Court Judge Robert Sweet cited the Supreme Court's prior rulings that patentable products must have "markedly different characteristics" from what is found in nature. 1 Purification alone, he held, does not change the es sential characteristic of DNAits nucleotide sequence. Indeed, the ability to reliably detect mu tations depends on this essen tial characteristic's remaining un changed.
Judge Sweet also rejected Myri ad's patent claims relating to the use of these DNA sequences in evaluating a patient's susceptibili ty to cancer. Building on the prin ciples outlined in a 2008 federal appeals court decision, In re Bilski, 5 he found these claims to be inap propriate subject matter for a pro cess patent because they related to "abstract mental processes" of "analyzing" or "comparing" and did not involve a transformative step in which matter was turned into a different state or thing. That is, the patented method con sisted only of comparing the nu cleotide sequence in a test sample to the reference sequence.
The Bilski case has been ar gued before the Supreme Court and is currently under consider ation; a decision that a transfor mation is not required for pat entability could undermine Judge Sweet's holding on Myriad's pro cess patents. Even murkier, how ever, is the fate of his decision about patents on the DNA se quences themselves. Although wellgrounded in legislative his tory and Supreme Court prece dent, flies in the face of years of decision making by the USPTO and is headed next to the Court of Appeals for the Federal Cir cuit, which is known for its friendliness to patent seekers.
How will the decision against Myriad Genetics, if upheld, af fect biotechnology research and development? Judge Sweet was careful to limit his holding to the patentability of isolated DNA se quences, as distinct from other compounds, writing that they are unique as "a physical embodiment of information." The decision thus will affect only a narrow segment of the biotechnology industry -but it may do so deeply. Genes themselves will be offlimits for patents, and in conjunction with Bilski, it is dif ficult to see how any tests that consist of comparing gene se quences will be patentable ei ther, because they do not involve a transformative step. Therefore, companies whose focus is the discovery of new genes and the development of tests that com pare DNA sequences would enter a new commercial landscape. Such tests could still be marketed but could face competition much sooner than they have in the past.
At the same time, research into aspects of our genome will remain an important avenue for public research funds, as it was in the discovery of the BRCA genes, and having fewer competing in tellectual property claims at the basicscience level may enhance the prospects for parties inter ested in building therapeutics based on this information. How any changes may affect innova tion is unclear at this point, but potential competitors for BRCA testing will almost certainly wait for the outcome of the appeal. If the Myriad decision is upheld, we will have seen the pendulum on the legal status of DNA pat ents swing back from the lack of restraint that has character ized the past two decades.
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